Nurix Therapeutics, Inc. (NRIX) is a Biotechnology company in the Healthcare sector, currently trading at $16.30. It has a SharesGrow Score of 58/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Analyst consensus target is NRIX = $31 (+91.5% upside).
Valuation: NRIX trades at a trailing Price-to-Earnings (P/E) of -5.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.44.
Financials: revenue is $84M, +41.4%/yr average growth. Net income is $264M (loss), growing at -19.3%/yr. Net profit margin is -314.9% (negative). Gross margin is 77.5% (+5.5 pp trend).
Balance sheet: total debt is $56M against $539M equity (Debt-to-Equity (D/E) ratio 0.1, conservative). Current ratio is 7.02 (strong liquidity). Debt-to-assets is 8.1%. Total assets: $688M.
Analyst outlook: 17 / 17 analysts rate NRIX as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 78/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 62/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).
